AR027773A1 - Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas - Google Patents
Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranasInfo
- Publication number
- AR027773A1 AR027773A1 ARP010101625A ARP010101625A AR027773A1 AR 027773 A1 AR027773 A1 AR 027773A1 AR P010101625 A ARP010101625 A AR P010101625A AR P010101625 A ARP010101625 A AR P010101625A AR 027773 A1 AR027773 A1 AR 027773A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- chronic
- acute
- treatment
- neuropathic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas para el tratamiento del dolor agudo, cronico y/o neuropático. Las composiciones farmacéuticas están comprendidas por unacombinacion terapéuticamente eficaz de un agonista parcial de receptores de nicotina y un agente analg ésico y un vehículo farmacéutico aceptable. El agenteanalgésico se selecciona de analgésicos opioides, antagonistas de NMDA, antagonistas de la sustancia P, inhibidores de COX 1 y COX 2, antidepresivostricíclicos (TCA), inhibidores de la reabsorcion de la serotonina selectivos (SSRI), agonistas de receptores de capsaicina, agentes anestésicos,benzodiazepinas, relajantes de los musculos esqueléticos, agentes terapéuticos para la migrana, anti-convulsionantes, anti-hipertensivos, anti-arrítmicos,a ntihistamínicos, esteroides, cafeína y toxina botulínica. También se describe el método para usar estos compuestos y un método para tratar el dolor agudo,cronico y/o neuropático y la migrana en un mamífero incluyendo un ser humano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19573800P | 2000-04-07 | 2000-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027773A1 true AR027773A1 (es) | 2003-04-09 |
Family
ID=22722582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101625A AR027773A1 (es) | 2000-04-07 | 2001-04-05 | Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas |
Country Status (35)
Country | Link |
---|---|
US (2) | US20010036943A1 (es) |
EP (1) | EP1272218B1 (es) |
JP (1) | JP2003530345A (es) |
KR (1) | KR20030040201A (es) |
CN (1) | CN1468111A (es) |
AP (1) | AP2002002642A0 (es) |
AR (1) | AR027773A1 (es) |
AT (1) | ATE291438T1 (es) |
AU (1) | AU3768001A (es) |
BG (1) | BG107138A (es) |
BR (1) | BR0109837A (es) |
CA (1) | CA2405142A1 (es) |
CR (1) | CR6767A (es) |
CZ (1) | CZ20023214A3 (es) |
DE (1) | DE60109589T2 (es) |
EA (1) | EA004930B1 (es) |
EE (1) | EE200200579A (es) |
ES (1) | ES2236185T3 (es) |
GT (1) | GT200100055A (es) |
HU (1) | HUP0301822A3 (es) |
IL (1) | IL152076A0 (es) |
IS (1) | IS6560A (es) |
MA (1) | MA26889A1 (es) |
MX (1) | MXPA02009817A (es) |
NO (1) | NO20024734D0 (es) |
OA (1) | OA12241A (es) |
PA (1) | PA8515001A1 (es) |
PE (1) | PE20011307A1 (es) |
PL (1) | PL365957A1 (es) |
SK (1) | SK13952002A3 (es) |
SV (1) | SV2002000377A (es) |
TN (1) | TNSN01053A1 (es) |
WO (1) | WO2001076576A2 (es) |
YU (1) | YU74602A (es) |
ZA (1) | ZA200207996B (es) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69722426T3 (de) | 1996-07-24 | 2015-05-07 | Warner-Lambert Company LLC (n.Ges. des Staates Delaware) | Isobutylgaba und dessen derivate zur schmerzbehandlung |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
WO2002026020A2 (en) * | 2000-09-26 | 2002-04-04 | The Brigham And Women's Hospital, Inc. | Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
US7074961B2 (en) | 2000-09-26 | 2006-07-11 | The Brigham And Women's Hospital, Inc. | Antidepressants and their analogues as long-acting local anesthetics and analgesics |
JP2004527545A (ja) * | 2001-04-20 | 2004-09-09 | ファイザー・プロダクツ・インク | 1,3−置換インデンおよびアリール縮合アザ多環式化合物の調製方法 |
ES2632544T3 (es) * | 2001-06-07 | 2017-09-14 | Analgesic Neuropharmaceuticals, Llc | Tratamiento de dolor neuropático con el antagonista del receptor de N-metil-D-aspartato (NMDA) dextrometorfano |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
US20040138239A1 (en) * | 2001-08-23 | 2004-07-15 | Bruce Frome | Compositions and methods for targeting cerebral circulation and treatment of headache |
EP1419161A1 (en) | 2001-08-24 | 2004-05-19 | PHARMACIA & UPJOHN COMPANY | Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease |
IL160884A0 (en) | 2001-10-02 | 2004-08-31 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
JP2005510523A (ja) | 2001-11-09 | 2005-04-21 | ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー | アザ二環式フェニル縮合複素環式化合物、及びα7NACHRリガンドとしての当該化合物の使用 |
WO2003049753A1 (en) * | 2001-12-13 | 2003-06-19 | Council Of Scientific And Industrial Research | Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof |
EP1471910A2 (en) * | 2002-01-17 | 2004-11-03 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors |
WO2003066040A1 (fr) * | 2002-02-05 | 2003-08-14 | Ajinomoto Co.,Inc. | Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n |
US20050096395A1 (en) * | 2002-02-12 | 2005-05-05 | Rao Srinivas G. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
US6858613B2 (en) | 2002-02-19 | 2005-02-22 | Pfizer Inc. | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease |
BR0307782A (pt) | 2002-02-19 | 2005-01-04 | Upjohn Co | Compostos azabiciclo para o tratamento de doença |
EP1499309A4 (en) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US20040014681A1 (en) * | 2002-05-14 | 2004-01-22 | Ralph Ryback | Method for treating dermatoses and tissue damage |
WO2003097043A1 (en) * | 2002-05-15 | 2003-11-27 | Abbott Laboratories | Treatment of neuropathic pain |
WO2003096991A2 (en) | 2002-05-17 | 2003-11-27 | Othera Pharmaceuticals, Inc. | Amelioration of the development of cataracts and other opthalmic diseases |
JP2006509735A (ja) * | 2002-10-17 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | オクスカルバゼピンまたはその誘導体およびcox2インヒビターからなる疼痛処置用医薬組成物 |
WO2004050688A1 (en) | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
EP1572725B1 (en) | 2002-12-02 | 2012-02-29 | Xenome Ltd | Chi-conotoxin peptides having a n-terminal pyroglutamic acid |
US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
DK1578422T3 (da) | 2002-12-20 | 2007-07-02 | Niconovum Ab | Fysisk og kemisk stabilt nikotin-indeholdende partikelholdigt materiale |
EP1599221B1 (en) * | 2003-03-06 | 2011-12-28 | Botulinum Toxin Research Associates, Inc. | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin |
EA008705B1 (ru) * | 2003-04-08 | 2007-06-29 | Алгоркс Фармасьютикалз, Инк. | Получение и очистка синтетического капсаицина |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
WO2005000806A2 (en) | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
US20050004219A1 (en) * | 2003-07-01 | 2005-01-06 | Medtronic, Inc. | Pump systems including injectable gabapentin compositions |
US20050004221A1 (en) * | 2003-07-01 | 2005-01-06 | Medtronic, Inc. | Intrathecal gabapentin compositions |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
WO2005032556A1 (en) | 2003-10-02 | 2005-04-14 | Elan Pharmaceuticals, Inc. | Method for reducing pain |
US20050090548A1 (en) * | 2003-10-23 | 2005-04-28 | Medtronic, Inc. | Intrathecal gabapentin for treatment of epilepsy |
US20050090549A1 (en) * | 2003-10-23 | 2005-04-28 | Medtronic, Inc. | Intrathecal gabapentin for treatment of pain |
AU2004291082A1 (en) * | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
HU230403B1 (hu) * | 2003-12-19 | 2016-04-28 | Pál Kocsis | Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
WO2005123043A2 (en) * | 2004-06-10 | 2005-12-29 | Duramed Pharmaceuticals, Inc. | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
JP2008517927A (ja) * | 2004-10-21 | 2008-05-29 | ユニバーシティー オブ アイオワ リサーチ ファンデーション | insitu制御放出薬剤送達システム |
US20080176873A1 (en) * | 2004-11-10 | 2008-07-24 | Trinity Laboratories, Inc. | Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria |
BRPI0516912A2 (pt) * | 2004-11-24 | 2009-06-23 | Algorx Pharmaceuticals Inc | formulação a base do capsaicinoide em gel e usos da mesma |
US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
EP1881959A1 (en) | 2005-05-20 | 2008-01-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
JP5694645B2 (ja) | 2006-03-16 | 2015-04-01 | ニコノヴァム エービーNiconovum Ab | 改善された嗅ぎたばこ組成物 |
JP2007308403A (ja) * | 2006-05-17 | 2007-11-29 | Kenji Yoshida | 皮膚外用剤 |
JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
CN101511388B (zh) * | 2006-07-17 | 2012-10-24 | 特拉维夫大学拉莫特有限公司 | 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途 |
WO2008020651A1 (fr) * | 2006-08-17 | 2008-02-21 | Kyushu University, National University Corporation | antagoniste de récepteur P2X4 |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
US7645767B2 (en) * | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
PL2081562T3 (pl) * | 2006-09-20 | 2017-05-31 | The Board Of Regents Of The University Of Texas System | Sposoby dostarczania lotnych środków znieczulających do znieczulenia regionalnego i/lub zmniejszania bólu |
US20100048605A1 (en) * | 2006-12-11 | 2010-02-25 | University Of Kentucky Research Foundation | Synergistic effects of combinations of nornicotine and opioids for the treatment of pain |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
JP5647519B2 (ja) | 2007-09-13 | 2014-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成 |
EP2381834A2 (en) * | 2008-01-31 | 2011-11-02 | Fund for Medical Research Development of Infrastructure & Health Services Rambam Medical Center | Method of predicting pain medication efficacy |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
EP3000462A1 (en) * | 2008-04-28 | 2016-03-30 | Zogenix, Inc. | Novel formulations for treatment of migraine |
BRPI0915890A2 (pt) | 2008-06-23 | 2015-11-03 | Janssen Pharmaceutica Nv | forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US20100184685A1 (en) * | 2009-01-19 | 2010-07-22 | Zavala Jr Gerardo | Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein |
PE20130243A1 (es) | 2010-06-15 | 2013-03-22 | Gruenenthal Chemie | Combinacion farmaceutica |
US8916610B2 (en) | 2010-09-22 | 2014-12-23 | Ramot At Tel-Aviv University Ltd. | Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same |
ME02874B (me) | 2010-12-22 | 2018-04-20 | Purdue Pharma Lp | Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu |
CN103327969A (zh) | 2010-12-23 | 2013-09-25 | 普渡制药公司 | 抗篡改固体口服剂型 |
US20130324608A1 (en) * | 2011-02-18 | 2013-12-05 | Yuanlong Pan | Methods and compositions for treating, reducing or preventing damage to the nervous system of animals |
ES2387973B1 (es) * | 2011-03-18 | 2013-10-01 | Dr Healthcare España, S. L. | Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor. |
US8580850B2 (en) | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
AU2013302468B2 (en) * | 2012-08-16 | 2017-08-24 | Janssen Pharmaceutica Nv | Substituted pyrazoles as N-type calcium channel blockers |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
CN104758933A (zh) * | 2014-10-29 | 2015-07-08 | 吴鑫欣 | 治疗神经卡压、神经瘤疼痛的药物和给药系统 |
EP3600385A4 (en) * | 2017-03-22 | 2021-04-07 | Bonti, Inc. | BOTULINUM NEUROTOXINS FOR THE TREATMENT OF TRAUMATIC INJURIES |
WO2018183320A1 (en) * | 2017-03-31 | 2018-10-04 | Depco, Inc. | Therapeutic putty having analgesics and/or counterirritants |
US10463638B2 (en) * | 2017-04-12 | 2019-11-05 | Synergistic Therapeutics, Llc | Therapeutic neuropathic pain lotion |
KR101944113B1 (ko) | 2017-09-28 | 2019-01-30 | 동의대학교 산학협력단 | 급성 안면통증 예방 및 개선용 조성물 |
KR102156627B1 (ko) | 2018-12-20 | 2020-09-16 | 동의대학교 산학협력단 | 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물 |
KR102156438B1 (ko) | 2018-12-20 | 2020-09-16 | 동의대학교 산학협력단 | 급성 안면통증 예방 및 개선용 조성물 |
CN115054601B (zh) * | 2022-03-21 | 2024-04-26 | 中山大学附属第三医院 | 一种可注射的缓释镇痛复合物及其制备方法、应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018798A1 (en) * | 1996-10-30 | 1998-05-07 | Pfizer Inc. | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
ES2213354T3 (es) * | 1998-04-29 | 2004-08-16 | Pfizer Products Inc. | Compuestos azapoliciclicos condensados con arilo. |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
-
2000
- 2000-12-18 US US09/740,307 patent/US20010036943A1/en not_active Abandoned
-
2001
- 2001-03-16 EE EEP200200579A patent/EE200200579A/xx unknown
- 2001-03-16 HU HU0301822A patent/HUP0301822A3/hu unknown
- 2001-03-16 CA CA002405142A patent/CA2405142A1/en not_active Abandoned
- 2001-03-16 CN CNA01816840XA patent/CN1468111A/zh active Pending
- 2001-03-16 YU YU74602A patent/YU74602A/sh unknown
- 2001-03-16 KR KR1020027013380A patent/KR20030040201A/ko not_active Application Discontinuation
- 2001-03-16 WO PCT/IB2001/000391 patent/WO2001076576A2/en not_active Application Discontinuation
- 2001-03-16 SK SK1395-2002A patent/SK13952002A3/sk not_active Application Discontinuation
- 2001-03-16 AP APAP/P/2002/002642A patent/AP2002002642A0/en unknown
- 2001-03-16 AT AT01910097T patent/ATE291438T1/de not_active IP Right Cessation
- 2001-03-16 ES ES01910097T patent/ES2236185T3/es not_active Expired - Lifetime
- 2001-03-16 IL IL15207601A patent/IL152076A0/xx unknown
- 2001-03-16 EA EA200200910A patent/EA004930B1/ru not_active IP Right Cessation
- 2001-03-16 CZ CZ20023214A patent/CZ20023214A3/cs unknown
- 2001-03-16 EP EP01910097A patent/EP1272218B1/en not_active Expired - Lifetime
- 2001-03-16 OA OA1200200304A patent/OA12241A/en unknown
- 2001-03-16 PL PL01365957A patent/PL365957A1/xx not_active Application Discontinuation
- 2001-03-16 AU AU37680/01A patent/AU3768001A/en not_active Abandoned
- 2001-03-16 MX MXPA02009817A patent/MXPA02009817A/es unknown
- 2001-03-16 BR BR0109837-3A patent/BR0109837A/pt not_active IP Right Cessation
- 2001-03-16 DE DE60109589T patent/DE60109589T2/de not_active Expired - Fee Related
- 2001-03-16 JP JP2001574094A patent/JP2003530345A/ja active Pending
- 2001-04-05 GT GT200100055A patent/GT200100055A/es unknown
- 2001-04-05 PE PE2001000319A patent/PE20011307A1/es not_active Application Discontinuation
- 2001-04-05 AR ARP010101625A patent/AR027773A1/es not_active Application Discontinuation
- 2001-04-06 SV SV2001000377A patent/SV2002000377A/es not_active Application Discontinuation
- 2001-04-06 TN TNTNSN01053A patent/TNSN01053A1/fr unknown
- 2001-04-09 PA PA20018515001A patent/PA8515001A1/es unknown
-
2002
- 2002-09-20 IS IS6560A patent/IS6560A/is unknown
- 2002-09-23 BG BG107138A patent/BG107138A/xx unknown
- 2002-10-02 NO NO20024734A patent/NO20024734D0/no not_active Application Discontinuation
- 2002-10-02 MA MA26846A patent/MA26889A1/fr unknown
- 2002-10-02 CR CR6767A patent/CR6767A/es unknown
- 2002-10-04 ZA ZA200207996A patent/ZA200207996B/en unknown
-
2003
- 2003-01-21 US US10/348,381 patent/US20030133951A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR027773A1 (es) | Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migranas | |
GT199700107A (es) | Lactamas e imidas heterociclicas de aralquilo y araquilideno | |
KR980000447A (ko) | 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 | |
EA200300183A1 (ru) | Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
DK0957914T4 (da) | Formulering af 5-HT-agonister | |
UY26052A1 (es) | Composiciones analgesicas que comprenden compuestos antiepilepticos y metodos para usarlas | |
BR0106462A (pt) | Composições farmacêuticas para distúrbios do snc e outros distúrbios | |
AR042463A1 (es) | Tratamiento del dolor con combinaciones de nalbufina y agonistas del receptor de opioides kappa y antagosnistas del receptor opioides | |
CU23226B7 (es) | COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS | |
PT1135153E (pt) | Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares | |
RS50070B (sr) | Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista | |
BRPI0409128A (pt) | uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável | |
CO4410317A1 (es) | Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos. | |
CO5670327A2 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion | |
ES2125567T3 (es) | Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña. | |
DK1303278T3 (da) | Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme | |
CO5160295A1 (es) | Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri | |
UY26660A1 (es) | Una composición farmacéutica para el tratamiento del dolor agudo, crónico y/o el dolor neuropático y las migranas | |
HUP0402358A3 (en) | Use of selective dopamine d4 receptor agonists for preparation of pharmaceutical composition for treating sexual dysfunction | |
BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos | |
TH63854A (th) | ส่วนผสมทางการปรุงยาสำหรับรักษาอาการปวดที่รุนแรง,เรื้อรังและ/หรืออาการปวดทางเส้นประสาทและไมเกรน | |
DE60329034D1 (de) | Orales antidepressivum enthaltend acetylsalicylsäure zur beschleunigung des wirkungseintritts | |
HUP0103544A2 (hu) | (R)-3-(N,N-diciklobutil amino)-8-fluor-3,4dihidro-2H-1-benzopirán-5karboxamid-hidrogén-(2R,3R)tartarát monohidrátot és paroxelint tartalmazó gyógyszerkészítmény és eljárás az előállítására | |
ECSP003378A (es) | Composiciones analgesicas que comprenden compuestos antiepilepticos y metodos para usarlas | |
ECSP003564A (es) | ANTAGONISTAS SELECTIVOS DEL RECEPTOR DE iG1uR5 PARA EL TRATAMIENTO DE LA MIGRAÑA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |